Core Viewpoint - Lepu Medical (300003.SZ) expects a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Financial Performance - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million and 1.2 billion yuan, with a year-on-year increase of 261.29% to 441.93% [1] - The company's core business in cardiovascular interventional revenue has shown steady growth, while the retail channel inventory clearance in the pharmaceutical sector has been largely completed, resulting in double-digit revenue growth [1] Business Stability and Cash Flow - The traditional business foundation remains solid, providing stable profits and cash flow for the company [1] - The strategic emerging sectors, including innovative drugs and dermatology, have contributed to performance growth, with net cash flow from operating activities increasing by approximately 95% [1]

Core Viewpoint - Lepu Medical announced an expected net profit attributable to shareholders of the listed company for 2025, ranging from 800 million to 1.2 billion yuan [2] Financial Forecast - The company projects a net profit for 2025 between 800 million yuan and 1.2 billion yuan [2]

Group 1 - The core business of cardiovascular interventional products has shown steady revenue growth, while the inventory clearance in the retail channel of the pharmaceutical segment is nearly complete, leading to double-digit revenue growth for Lepu Medical [1] - Lepu Medical forecasts a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [3] - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million to 1.2 billion yuan, with a year-on-year increase of 261.29% to 441.93% [3]

Core Viewpoint - Lepu Medical (300003) forecasts a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Financial Performance - The company's core business in cardiovascular interventional revenue is steadily increasing [1] - The retail channel inventory cleanup in the pharmaceutical sector is nearly complete, leading to double-digit revenue growth [1] - The traditional business foundation remains solid, providing stable profits and cash flow [1] Group 2: Strategic Developments - The strategic emerging sectors, including innovative drugs and dermatology, have contributed to performance growth [1] - The net cash flow from operating activities has increased by approximately 95% [1]

Core Viewpoint - Lepu Medical (300003.SZ) forecasts a net profit of 800 million to 1.2 billion yuan for the year 2025, indicating a year-on-year growth of 223.97% to 385.95% [1] Financial Performance - The company expects a net profit attributable to shareholders of 800 million to 1.2 billion yuan, reflecting a significant increase compared to the previous year [1] - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million to 1.2 billion yuan, with a year-on-year growth of 261.29% to 441.93% [1]

Core Viewpoint - Lepu Medical (300003.SZ) forecasts a net profit attributable to shareholders of 800 million to 1.2 billion yuan for the year 2025, indicating a year-on-year growth of 223.97% to 385.95% [1] Financial Performance - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million to 1.2 billion yuan, reflecting a year-on-year increase of 261.29% to 441.93% [1]

Core Viewpoint - The company expects a net profit of 800 million to 1.2 billion yuan for the fiscal year 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Financial Performance - The core business of cardiovascular interventional revenue is steadily increasing [1] - The retail channel inventory clearance in the pharmaceutical sector's formulation business is nearly complete, achieving double-digit revenue growth [1] - The traditional business foundation remains solid, providing stable profits and cash flow for the company [1] Group 2: Strategic Developments - The strategic emerging sectors, including innovative drugs and dermatology, have contributed to performance growth [1] - The net cash flow generated from operating activities has increased by approximately 95% [1]

Core Viewpoint - Lepu Medical (300003.SZ) expects a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Business Performance - The growth is primarily driven by steady increases in the cardiovascular interventional business and the completion of inventory clearance in the pharmaceutical retail channel, leading to double-digit growth in formulation revenue [1] - Contributions from innovative drugs and emerging sectors such as dermatology are also significant [1] Group 2: Financial Developments - The company received a $30 million upfront payment for the MWN105 project under a licensing agreement [1] Group 3: Cost Management - Personnel optimization and organizational restructuring have led to a decrease in sales and management expenses [1]

证券代码：300003 证券简称：乐普医疗 公告编号：2026-003 乐普（北京）医疗器械股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1、报告期内公司核心业务心血管植介入营业收入稳中有升，药品板块中制 剂业务零售渠道的库存清理基本完成，营业收入实现双位数增长。传统业务基本 盘稳固，为公司提供了稳定的利润和现金流。此外公司布局的战略新兴板块中， 创新药和皮肤科业务贡献了业绩增量，公司经营活动产生的现金流量净额实现增 长约 95%。 2、报告期内公司控股子公司民为生物将具有自主知识产权的 MWN105 注 1 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 | 盈利：80,000万元～120,000万元 | 盈利：24,693.77万元 | | 股东的净利润 | 比上年同期增长：223.97%～385 ...

Core Insights - The coronary access devices are essential consumables for percutaneous coronary intervention (PCI) surgeries, directly impacting surgical outcomes and complication control [1][6] - The industry is supported by a series of policies in China, including centralized procurement, innovation approvals, and grassroots medical construction, laying a solid foundation for high-quality development [6][10] - The number of coronary artery disease patients is steadily increasing globally and in China, with projections indicating 220 million patients worldwide and 27.879 million in China by 2024, highlighting significant growth potential for the industry [10] Industry Overview - Coronary access devices are specialized medical equipment and consumables used in PCI surgeries to establish and maintain access from the body surface to the coronary arteries, ensuring the smooth execution of angiography, balloon dilation, and stent implantation [1][6] - The devices are categorized into four main types: puncture devices, catheter systems, sheath sets, and auxiliary devices for pressure monitoring and vascular closure [3][4] Development Background - The development of coronary access devices is crucial for reducing cardiovascular disease mortality, enhancing medical accessibility, and promoting high-end device localization [6][8] - Recent policies in China aim to improve centralized procurement mechanisms, accelerate innovation device approvals, and standardize medical insurance payments, providing guidance for industry development [6][10] Market Analysis - The global coronary balloon dilatation catheter market is expanding, with functional balloons growing at a faster rate; the market size is expected to increase from $560 million in 2020 to $960 million in 2024, with a compound annual growth rate (CAGR) of 8.49% [12][14] - In China, the market is characterized by structural adjustments and rapid growth, with the general balloon market experiencing a temporary decline due to centralized procurement but expected to rebound, while functional balloons are projected to grow significantly, with a CAGR of 19.28% from 2024 to 2028 [14][16] Competitive Landscape - The competitive landscape of the coronary access device industry is tiered, with foreign companies dominating the high-end market while domestic leaders are accelerating their market penetration; by 2024, domestic companies are expected to capture 54.9% of the coronary balloon market [14][15] Future Trends - The industry is expected to evolve along three main directions: technological upgrades, deepening domestic substitution, and expansion of grassroots markets [16] - Innovations such as biodegradable materials and smart functions will drive high-end product iterations, while local companies will enhance core component localization through material and manufacturing process advancements [17][18] - The promotion of tiered diagnosis and treatment will reshape market demand, with a growing need for cost-effective and standardized products suitable for grassroots settings [18]